Overall, therapy with sofosbuvir plus ribavirin for 12 weeks seems be a potent and promising regimen for HCV genotype 2 patients, but for other HCV genotypes, especially in patients with liver cirrhosis, alternative strategies such as longer treatment durations, or the addition of another DAA or of PEG-IFN-α appear to be necessary. The gene discussed is IFNA1; the disease is cirrhosis of liver.